GO:0006177 GMP biosynthetic process: Purine Nucleotide Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006177 (GMP biosynthetic process) describes the chemical reactions and pathways that result in the formation of guanosine monophosphate (GMP), a core purine nucleotide.
• GMP biosynthesis is a branch of purine metabolism that converts IMP-derived intermediates into GMP through two sequential enzymatic steps, and it is tightly coupled to cGMP and c-di-GMP signaling.
• The pathway is essential because GMP is a precursor for RNA, DNA, and the second messengers cGMP and c-di-GMP that control motility, biofilm formation, and virulence.
• Key enzymes include GMP synthase (GMPS/guA) and IMP dehydrogenase (IMPDH/guB), which are conserved from bacteria to humans and are validated drug targets.
• Dysregulation of GMP biosynthesis is linked to bacterial pathogenesis, biofilm-associated infections, and protozoan cGMP-dependent signaling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of GMP biosynthetic genes in bacteria, protozoa, and mammalian cells.
Description
Guanosine monophosphate (GMP) is a purine ribonucleotide that serves as a building block of RNA and DNA and as the precursor of the signaling molecules cyclic GMP (cGMP) and cyclic di-GMP (c-di-GMP). The Gene Ontology term GO:0006177, GMP biosynthetic process, defines the chemical reactions and pathways resulting in the formation of GMP. This process sits at the intersection of central nucleotide metabolism and second-messenger biology, making it a recurring focus in microbiology, parasitology, and cancer research. In bacteria, GMP biosynthesis feeds the c-di-GMP pool that governs biofilm formation, motility, and virulence, and c-di-GMP has been shown to regulate bacterial NAD biosynthesis via the transcriptional repressor NadR. In protozoa, cGMP produced from GMP drives protein kinase signaling pathways that control growth and differentiation. Because these pathways are absent or structurally distinct in humans, the enzymes of GMP biosynthesis are attractive antimicrobial and antiparasitic targets. For researchers, GO:0006177 provides a precise annotation framework for interpreting transcriptomic, proteomic, and genetic screens. Understanding which genes carry the GMP biosynthetic annotation, and how their loss or mutation reshapes nucleotide pools and downstream signaling, is central to mechanistic studies of infection, biofilm biology, and nucleotide-dependent disease.
GMP biosynthetic process At A Glance
| GO ID | GO:0006177 |
|---|---|
| GO term | GMP biosynthetic process |
| Ontology | biological_process |
| Synonym | GMP anabolism; GMP biosynthesis; GMP formation; GMP synthesis |
| Major function | Formation of guanosine monophosphate (GMP) from purine precursors |
| Pathway branch | Purine nucleotide biosynthesis (guanine branch) |
| Key intermediates | IMP, XMP, GMP |
| Representative enzymes | IMP dehydrogenase (IMPDH/guB), GMP synthase (GMPS/guA) |
| Downstream products | GDP, GTP, cGMP, c-di-GMP, RNA, DNA |
What Is GO:0006177?
GO:0006177, GMP biosynthetic process, is the biological process comprising all chemical reactions and pathways that lead to the formation of guanosine monophosphate (GMP). It covers the enzymatic conversion of purine intermediates into GMP, including the amination of xanthosine monophosphate (XMP) to GMP and the upstream oxidation steps that generate XMP from inosine monophosphate (IMP). The term is synonymous with GMP anabolism, GMP biosynthesis, GMP formation, and GMP synthesis, and it is classified under the biological_process aspect of the Gene Ontology.
Why Is GMP biosynthetic process Important in Cell Biology?
GMP biosynthetic process matters because GMP is not only a structural nucleotide but also the direct precursor of cGMP and c-di-GMP, two second messengers that control bacterial biofilm formation, motility, virulence, and protozoan protein kinase signaling. The pathway is also a validated antimicrobial target: small molecules that interfere with c-di-GMP signaling and biofilm formation act downstream of GMP biosynthesis, and c-di-GMP itself regulates bacterial NAD biosynthesis through NadR. Because the enzymes of GMP biosynthesis are conserved and genetically tractable, the term provides a precise annotation anchor for functional genomics, drug discovery, and CRISPR-based validation studies.
• GMP is a precursor for RNA and DNA synthesis, making the pathway essential for cell growth and division.
• GMP is the direct precursor of cGMP, a second messenger in protozoan protein kinase signaling.
• GMP-derived c-di-GMP controls bacterial biofilm formation, motility, and virulence.
• c-di-GMP regulates bacterial NAD biosynthesis via the transcriptional repressor NadR, linking GMP metabolism to redox and energy metabolism.
• The diversity of c-di-GMP-binding proteins makes GMP biosynthesis a hub for signal integration.
• Enzymes of GMP biosynthesis are attractive targets for anti-biofilm and antimicrobial small molecules.
• Dysregulated purine nucleotide metabolism is associated with cancer and immune dysfunction, motivating studies of GMP pathway genes in mammalian cells.
• CRISPR screens can identify GMP biosynthetic genes required for pathogen survival and biofilm persistence.
• The pathway is conserved from bacteria to humans, enabling comparative and translational research.
• Accurate GO:0006177 annotation improves enrichment analysis in transcriptomic and proteomic studies of infection and metabolism.
What Happens During GMP biosynthetic process?
Step 1: IMP dehydrogenase converts IMP to XMP
In simple terms: The pathway starts by oxidizing a purine intermediate called IMP into XMP.
The first committed step of the guanine branch of purine biosynthesis is the NAD+-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), catalyzed by IMP dehydrogenase (IMPDH in eukaryotes, guaB/guB in bacteria). This reaction introduces the oxygen that distinguishes guanine nucleotides from adenine nucleotides and commits the intermediate to GMP formation. Because IMPDH is conserved and rate-limiting, it is a frequent target of antimicrobial and immunosuppressive compounds, and its activity is coupled to cellular redox state through NAD+/NADH balance.
Step 2: GMP synthase aminates XMP to GMP
In simple terms: XMP is then converted into GMP by adding an amino group.
GMP synthase (GMPS in eukaryotes, guaA in bacteria) catalyzes the ATP-dependent amination of XMP to form GMP, using glutamine as the nitrogen donor. This second step completes the GMP biosynthetic process and produces the guanosine monophosphate that feeds into GDP, GTP, RNA, DNA, cGMP, and c-di-GMP pools. GMP synthase is a bifunctional enzyme in many organisms, and its activity is essential for maintaining guanine nucleotide homeostasis.
Step 3: Feed-forward into cGMP and c-di-GMP signaling
In simple terms: GMP is converted into cyclic messengers that control cell behavior.
Once formed, GMP is phosphorylated to GDP and GTP, which serve as substrates for guanylate cyclases that produce cGMP and for diguanylate cyclases that produce c-di-GMP. cGMP acts as a second messenger in protozoan protein kinase pathways, while c-di-GMP is a bacterial second messenger that regulates biofilm formation, motility, and virulence. The diversity of c-di-GMP-binding proteins allows a single nucleotide signal to control many downstream outputs, including NAD biosynthesis via NadR.
Step 4: Regulation of GMP pool homeostasis
In simple terms: Cells tune how much GMP is made to match demand.
GMP biosynthesis is regulated by feedback inhibition, transcriptional control, and allosteric modulation of IMPDH and GMP synthase. In bacteria, c-di-GMP metabolism is itself regulated to balance biofilm and motile lifestyles, and c-di-GMP levels influence NAD biosynthesis through NadR. In protozoa, cGMP-dependent protein kinases transduce signals that depend on GMP availability. These regulatory layers ensure that GMP supply matches the needs of nucleic acid synthesis and second-messenger signaling.
Key Genes Involved in GO:0006177 GMP biosynthetic process
The following genes and proteins are experimentally implicated in GMP biosynthetic process (GO:0006177) and its downstream cGMP/c-di-GMP signaling, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IMPDH (guaB) | Oxidizes IMP to XMP in the first committed step of GMP biosynthesis | Rate-limiting enzyme; target for antimicrobial and immunosuppressive studies |
| GMPS (guaA) | Aminates XMP to GMP using glutamine and ATP | Essential for guanine nucleotide homeostasis; knockout causes GMP auxotrophy |
| NadR | Transcriptional repressor regulated by c-di-GMP that controls NAD biosynthesis | Links GMP-derived c-di-GMP to bacterial NAD metabolism |
| Diguanylate cyclases | Synthesize c-di-GMP from GTP | Control biofilm formation and motility; downstream of GMP biosynthesis |
| Phosphodiesterases | Degrade c-di-GMP | Regulate c-di-GMP turnover and biofilm dispersal |
| c-di-GMP-binding proteins | Effector proteins that bind c-di-GMP and alter behavior | Diverse mechanisms of signal transduction |
| cGMP-dependent protein kinases | Protozoan kinases activated by cGMP | Mediate cGMP signaling in protozoa |
| Guanylate cyclases | Convert GTP to cGMP | Produce cGMP from GMP-derived GTP |
| GuaA/GuaB operon regulators | Control expression of GMP biosynthetic enzymes | Transcriptional regulation of the pathway |
| NadR regulon genes | NAD biosynthesis genes repressed by NadR | Connect c-di-GMP to NAD homeostasis |
| Biofilm matrix genes | Structural components regulated by c-di-GMP | Phenotypic output of GMP-derived signaling |
| Motility genes | Flagellar and pili genes regulated by c-di-GMP | Phenotypic output of GMP-derived signaling |
| Virulence factors | Pathogenicity genes controlled by c-di-GMP | Link GMP biosynthesis to infection |
| Small-molecule targets | Proteins targeted by anti-biofilm compounds | Drug discovery against c-di-GMP signaling |
| cGMP-immunoreactive proteins | Proteins detected by cGMP immunocytochemistry | Mapping cGMP signaling in tissues |
| Purine salvage enzymes | Recycle guanine bases into GMP | Cross-talk with de novo GMP biosynthesis |
| Nucleotide kinases | Phosphorylate GMP to GDP and GTP | Connect GMP to energy and signaling pools |
How Is GMP biosynthetic process Regulated?
GMP biosynthetic process is regulated at multiple levels. In bacteria, c-di-GMP metabolism is controlled by the opposing activities of diguanylate cyclases and phosphodiesterases, which together set the cellular c-di-GMP concentration and thereby biofilm and motility programs. c-di-GMP also regulates bacterial NAD biosynthesis by targeting the transcriptional repressor NadR, providing a direct link between GMP-derived signaling and NAD homeostasis. The diversity of c-di-GMP-binding proteins allows the signal to be interpreted by many effectors, including transcription factors and enzymes. In protozoa, cGMP-dependent protein kinases transduce cGMP signals that depend on GMP availability, and their activity is regulated by cyclic nucleotide levels. Small molecules that target c-di-GMP signaling can modulate biofilm formation and bacterial motility, demonstrating that the pathway is druggable.
GMP biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IMPDH (guaB) | Bacterial biofilm infections; purine metabolism disorders | CRISPR knockout in bacterial strains; enzymatic assays |
| GMPS (guaA) | GMP auxotrophy; antimicrobial target | Conditional knockout and complementation in bacteria |
| NadR | c-di-GMP-dependent NAD biosynthesis dysregulation | Point-mutation of c-di-GMP binding site; NAD flux assays |
| Diguanylate cyclases | Biofilm-associated chronic infections | Overexpression and knockout in biofilm models |
| cGMP-dependent protein kinases | Protozoan growth and differentiation defects | Knockout and kinase-dead knock-in in protozoa |
Bacterial biofilm-associated infections
GMP-derived c-di-GMP is a central regulator of biofilm formation and virulence in bacterial pathogens. High c-di-GMP levels promote the production of biofilm matrix components and repress motility, contributing to chronic and device-associated infections. Because c-di-GMP is synthesized downstream of GMP biosynthesis, enzymes of GO:0006177 are candidate targets for anti-biofilm therapies, and small molecules that interfere with c-di-GMP signaling have been explored as biofilm inhibitors.
Metabolic crosstalk with NAD biosynthesis
c-di-GMP regulates bacterial NAD biosynthesis via the transcriptional repressor NadR, linking GMP-derived signaling to redox and energy metabolism. This crosstalk means that perturbations in GMP biosynthesis can indirectly reshape NAD pools and NAD-dependent processes, with implications for bacterial fitness and antibiotic susceptibility.
Protozoan cGMP-dependent signaling
In protozoa, cGMP produced from GMP-derived GTP activates cGMP-dependent protein kinases that control growth, differentiation, and host interaction. Disruption of cGMP signaling impairs protozoan viability, making the GMP biosynthetic pathway and its downstream kinases potential antiparasitic targets.
Nucleotide metabolism in cancer and immunity
Purine nucleotide biosynthesis, including the guanine branch that produces GMP, is required for rapid cell proliferation, and its dysregulation is associated with cancer and immune dysfunction. cGMP immunocytochemistry has been used to map cGMP signaling in tissues, providing a tool to study how GMP availability affects cyclic nucleotide-dependent physiology.
From GMP biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is IMPDH essential for GMP biosynthesis and bacterial growth? | CRISPR knockout of guaB with complementation |
| Does a point mutation in the NadR c-di-GMP binding site alter NAD biosynthesis? | Point-mutation knock-in of NadR |
| Can GMP synthase be tagged to track pathway localization? | Tagged knock-in of guaA/GMPS |
| Does overexpression of diguanylate cyclase increase biofilm formation? | Overexpression of diguanylate cyclase in bacterial biofilm assays |
| Does loss of cGMP-dependent protein kinase impair protozoan growth? | CRISPR knockout in protozoan parasites |
| Which genes are required for c-di-GMP-dependent virulence? | CRISPR library screening in bacterial pathogens |
How to Study the GMP biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene essentiality and pathway requirement | Testing guaB/guaA requirement for growth |
| Complementation assay | Restoration of wild-type phenotype | Confirming specific gene function |
| cGMP immunocytochemistry | Localization and levels of cGMP | Mapping cGMP signaling in tissues |
| c-di-GMP quantification | Cellular c-di-GMP concentration | Linking GMP biosynthesis to biofilm regulation |
| Biofilm assay | Biofilm biomass and architecture | Phenotypic readout of c-di-GMP signaling |
| Motility assay | Swimming and swarming behavior | Phenotypic readout of c-di-GMP signaling |
| Small-molecule screen | Inhibition of biofilm and motility | Drug discovery targeting c-di-GMP signaling |
| NAD flux assay | NAD biosynthesis rate | Testing c-di-GMP-NadR crosstalk |
Genetic knockout and complementation
CRISPR knockout of GMP biosynthetic genes such as guaB and guaA, followed by complementation, is a standard approach to test essentiality and pathway requirement. Loss of GMP biosynthesis typically produces guanine auxotrophy, which can be scored by growth in defined media, and complemented strains restore wild-type phenotypes.
Second-messenger quantification
Because GMP feeds into cGMP and c-di-GMP, quantifying these cyclic nucleotides is central to pathway studies. cGMP immunocytochemistry has been used to localize cGMP in tissues, while c-di-GMP levels can be measured by mass spectrometry or reporter systems to link GMP biosynthesis to biofilm and motility outputs.
Phenotypic assays for biofilm and motility
Biofilm formation and motility are classic readouts of c-di-GMP signaling downstream of GMP biosynthesis. Crystal violet biofilm assays, confocal microscopy, and swimming/swarming motility assays are used to test whether genetic or chemical perturbations of the pathway alter these phenotypes.
Small-molecule and chemical biology screens
High-throughput screens for compounds that target c-di-GMP signaling, biofilm formation, and bacterial motility provide a chemical biology approach to interrogate GMP biosynthetic output. Such screens can identify inhibitors of diguanylate cyclases or activators of phosphodiesterases that reduce biofilm formation.
How CRISPR Can Be Used to Study GO:0006177 GMP biosynthetic process
Knockout
CRISPR knockout of GMP biosynthetic genes such as guaB (IMPDH) and guaA (GMPS) is used to test whether the pathway is essential for growth, biofilm formation, and virulence. Knockout strains typically require exogenous guanine for growth, and their phenotypes can be rescued by complementation, providing causal evidence for gene function in GO:0006177.
Point Mutation
Point mutations can be introduced into catalytic residues of IMPDH or GMP synthase to dissect enzymatic mechanism, or into the c-di-GMP binding site of NadR to test signal transduction. Such point-mutation models separate catalytic activity from regulatory function and are valuable for structure-function studies of the pathway.
Knock-in
Tagged knock-in of GMP biosynthetic enzymes, for example with fluorescent or affinity tags, enables localization, interaction, and stability studies. Knock-in of reporter alleles can also be used to monitor pathway expression in real time under conditions that induce biofilm formation or virulence.
Overexpression
Overexpression of diguanylate cyclases or GMP biosynthetic enzymes increases c-di-GMP or GMP flux and is used to test sufficiency for biofilm formation, motility changes, or NAD biosynthesis regulation. Overexpression models complement knockout studies by demonstrating that elevated pathway activity is sufficient to drive downstream phenotypes.
How EDITGENE Supports GMP biosynthetic process Research
Researchers studying GMP biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in nucleotide metabolism, second-messenger signaling, or biofilm-associated phenotypes. EDITGENE provides CRISPR-based cell models and screening services that allow precise, reproducible interrogation of GO:0006177 genes across bacterial, protozoan, and mammalian systems.
Contact EDITGENE today to design your custom CRISPR model for GMP biosynthetic process research.
Frequently Asked Questions About GMP biosynthetic process
What is GMP biosynthetic process (GO:0006177)?
GO:0006177 is the Gene Ontology biological process describing the chemical reactions and pathways that result in the formation of guanosine monophosphate (GMP), a purine nucleotide and precursor of cGMP and c-di-GMP.
What genes are involved in GMP biosynthetic process?
Key genes include IMPDH (guaB), which oxidizes IMP to XMP, and GMPS (guaA), which aminates XMP to GMP; downstream effectors include diguanylate cyclases, phosphodiesterases, and c-di-GMP-binding proteins such as NadR.
Why is GMP biosynthesis important in bacteria?
GMP-derived c-di-GMP controls biofilm formation, motility, and virulence, and it regulates NAD biosynthesis via NadR, making the pathway central to bacterial physiology and pathogenesis.
How is GMP biosynthetic process regulated?
It is regulated by feedback inhibition and transcriptional control of IMPDH and GMP synthase, and by the opposing activities of diguanylate cyclases and phosphodiesterases that set c-di-GMP levels.
What is the difference between GMP and c-di-GMP?
GMP is a linear purine nucleotide used in RNA and DNA synthesis, while c-di-GMP is a cyclic dinucleotide second messenger synthesized from GTP that regulates bacterial behavior.
Can CRISPR be used to study GMP biosynthetic genes?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of GMP biosynthetic gene function in bacteria, protozoa, and mammalian cells.
What diseases are linked to GMP biosynthesis?
GMP biosynthesis is linked to bacterial biofilm-associated infections, c-di-GMP-dependent virulence, protozoan cGMP signaling defects, and broader purine metabolism disorders.
What methods are used to study GMP biosynthetic process?
Common methods include CRISPR knockout and complementation, cGMP immunocytochemistry, c-di-GMP quantification, biofilm and motility assays, and small-molecule screens.
What is the role of NadR in GMP-related signaling?
NadR is a transcriptional repressor that is targeted by c-di-GMP to regulate bacterial NAD biosynthesis, linking GMP-derived signaling to NAD homeostasis.
How can EDITGENE help with GMP biosynthetic process research?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services to dissect GMP biosynthetic pathway genes and their downstream phenotypes.
Conclusion
GO:0006177, GMP biosynthetic process, defines the enzymatic route that produces guanosine monophosphate, a nucleotide at the crossroads of nucleic acid synthesis and cyclic dinucleotide signaling. Its enzymes, including IMPDH and GMP synthase, are conserved, genetically tractable, and druggable, while its products feed cGMP and c-di-GMP pathways that control biofilm formation, motility, virulence, and NAD homeostasis. Because the pathway connects metabolism to second-messenger biology, it is a productive target for CRISPR-based functional studies. Knockout, point-mutation, knock-in, and overexpression models, combined with CRISPR library screening and bioinformatics, allow researchers to move from annotation to causal mechanism and to identify new intervention points for biofilm-associated infections and related diseases.
References
- 1. Mao L et al.. 2025. c-di-GMP regulates bacterial NAD biosynthesis via targeting the transcriptional repressor NadR.. mBio 16(9):e0198225 PMID: 40823837
- 2. de Vente J et al.. 1997. cGMP-immunocytochemistry.. Methods Mol Biol 72:125-43 PMID: 9249741
- 3. Chou SH et al.. 2016. Diversity of Cyclic Di-GMP-Binding Proteins and Mechanisms.. J Bacteriol 198(1):32-46 PMID: 26055114
- 4. Römling U et al.. 2006. Cyclic di-GMP as a second messenger.. Curr Opin Microbiol 9(2):218-28 PMID: 16530465
- 5. Hall CL et al.. 2018. Cyclic-di-GMP regulation of virulence in bacterial pathogens.. Wiley Interdiscip Rev RNA 9(1) PMID: 28990312
- 6. Jonas K et al.. 2009. Regulation of c-di-GMP metabolism in biofilms.. Future Microbiol 4(3):341-58 PMID: 19327118
- 7. Opoku-Temeng C et al.. 2017. Targeting c-di-GMP Signaling, Biofilm Formation, and Bacterial Motility with Small Molecules.. Methods Mol Biol 1657:419-430 PMID: 28889311
- 8. Baker DA et al.. 2005. Cyclic GMP-dependent protein kinases in protozoa.. Front Biosci 10:1229-38 PMID: 15769621
